• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
75,273.45 1,205.00
( 1.63%)
Global Indices
Nasdaq
46,146.75 -82.73
(-0.18%)
Dow Jones
6,578.03 -23.97
(-0.36%)
Hang Seng
53,715.15 1,462.87
(2.80%)
Nikkei 225
10,078.37 113.21
(1.14%)
Forex
USD-INR
93.53 0.04
(0.04%)
EUR-INR
108.22 0.07
(0.07%)
GBP-INR
125.01 0.33
(0.27%)
JPY-INR
0.59 0.00
(0.23%)

EQUITY - MARKET SCREENER

Ajanta Pharma Ltd
Industry :  Pharmaceuticals - Indian - Formulations
BSE Code
ISIN Demat
Book Value()
532331
INE031B01049
330.3875196
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
AJANTPHARM
37.92
35762.82
EPS(TTM)
Face Value()
Div & Yield %
75.48
2
0.98
 

hcl technologies ltd
Maruti Suzuki clocks total sales of 2.13 lakh units in Feb'26; exports jump 56% YoY
Mar 02,2026

Total domestic sales stood at 174,840 units during the period under review, marginally higher by 0.3% compared with 174,379 units last year.

Domestic passenger vehicle sales remained flat at 161,000 units (up 0.1% YoY) in February 2026, as gains in utility vehicle sales offset weakness in the entry level segments.

LCV volumes rose 15.5% to 3,130 units, while supplies to other OEMs declined 1.5% to 10,710 units in February 2026 over February 2025.

Exports rose sharply by 56.5% YoY to 39,155 units in February 2026, significantly outpacing overall growth and increasing their contribution to total volumes during the month.

In a separate filing, Maruti Suzuki India stated that the total production during February 2026 stood at 227,550 units, compared with 197,471 units in February 2025, registering a growth of 15.2% YoY.

Maruti Suzuki India is engaged in the manufacture, purchase, and sale of motor vehicles, components, and spare parts (automobiles).

The company reported a 4.08% YoY increase in net profit to Rs 3,879.1 crore in Q3 FY26, compared with Rs 3,726.9 crore in Q3 FY25, while revenue from operations rose 28.74% YoY to Rs 49,904.1 crore.

The scrip fell 1.82% to currently trade at Rs 14599.05 on the BSE.